Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsSupportive Therapy, ToxicityProtocol groupComplicationsGynecological OncologyPlasma cell neoplasmsDiseaseBone MetastasesHypercalcemia of MalignancyMultiple MyelomaOsteolysisSubgroupICD10C79.5C90.-C90.0-E83.59M89.5-MeSHHypercalcemiaMultiple MyelomaOsteolysisPlasmacytomaSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionClodronic acidDenosumabIbandron AcidZoledronic AcidSupportive substanceBalanced Crystalloid SolutionClodronic acidDenosumabIbandron AcidZoledronic AcidSupportive substanceBalanced Crystalloid SolutionClodronic acidDenosumabIbandron AcidZoledronic AcidSupportive substanceBalanced Crystalloid SolutionClodronic acidDenosumabIbandron AcidZoledronic AcidNo. Substances12Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentionsupportiveRisksBone PainCardiotoxicityCataractDiarrheaDyspneaEmetogenicityHeadacheHypocalcemiaHypophosphatemiaOsteonecrosis of the JawPainRenal Failure only studiesPublicationAuthorBody JLipton AMorgan GJPaterson ARaje NRosen LDiseaseBrustkrebs bedingte KnochenmetastasenMamma-Ca mit KnochenmetastasenMamma-Ca mit Knochenmetastasen, ECOG 0-2Mamma-Ca mit Knochenmetastasen, ECOG 0-3mind. 1 Knochenmetastase beim Mamma-Ca mit ECOG 0-2 oder 1 osteolytsche Läsion beim MM Stadium IIINeudiagnostiziertes, multiples Myelom, Erstlinie in Kombination mit der Induktion und als Erhaltung für alle Patientenneu diagnostiziertes multiples Myelom mit mind. einer lytischen KnochenläsionOriginCenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, USADepartment of Medicine, Tom Baker Cancer Centre, University of Calgary and Alberta Cancer Board, Edmonton, CanadaDevelopmental Therapeutics, Cancer Institute Medical Group, Santa Monica, CaliforniaMRC Myelom IX StudiePenn State Milton S. Hershey Medical Center Oncology, Hershey, PAUniversité Libre de Bruxelles, Institut Jules Bordet, Brussels, BelgiumUniversité Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium, MF 4265 Study GroupProtocols in Revision 7 protocols foundProtocols under revision.Clodronic Acid 1040/520, Bone Metastases (PID945 V1.0)Denosumab 120, Bone Metastases (PID541 V1.1)Denosumab 120, multiple myleoma (PID1163 V1.0)IbandronAcid 50, Bone Metastases (PID948 V1.0)IbandronAcid 6, Bone Metastases (PID937 V1.0)Zoledronate 4, Bone Metastases (PID936 V1.0)Zoledronate 4, Multiple Myeloma (PID351 V2.0)
